Champions Oncology, Inc.
26.7.2021 14:32:22 CEST | ACCESS Newswire | Press release
HACKENSACK, NJ / ACCESSWIRE / July 26, 2021 / Champions Oncology, Inc. (NASDAQ:CSBR), a leading global oncology technology solutions provider that is transforming drug discovery through innovative pharmacology, biomarker, and data platforms, announced today an expansion of its corporate strategy as they unveil their entry into the drug discovery and development space. Champions is organized as a dynamic ecosystem of business units centered around a world leading oncology research center that is based off a unique & proprietary set of data and experimental platforms. The corporate composition of the company includes three business units (1) the foundational Research Services Business, (2) the recently launched Research Software Business with its flagship product, Lumin Bioinformatics, and (3) the newly announced Discovery and Innovation Business.
The rollout of the discovery and innovation business is the natural evolution for Champions as it continues to unlock the value contained within the rare dataset that has been amassed over the past twelve years. The tumor bank, and the dataset that has been derived, are unique for several reasons. First, unlike most other tumor models used in research, Champions' PDX models are highly representative of tumors present within a clinical setting. Thus, the datasets established using Champions' models provide more accurate and relevant insights. Second, the approach of using a ‘living tumor bank' of PDX models provides for a perpetual source of tumor, enabling a continuous and deep level of characterization. Specifically, Champions' scientists can establish multiple drug response datasets from the same tumor or re-interrogate these tumors with newly approved drugs or drug combinations. This also allows for a full characterization of the molecular nature of these tumors using multiple analytical methods. As new technologies emerge or are optimized, such as proteomic analysis, it is also possible to acquire and integrate this new data into the existing dataset. Third, by leveraging a ‘living tumor bank' of PDX models, it is possible to manipulate these tumors and simulate important therapeutic or molecular scenarios that are otherwise unavailable in other tumor models.
To demonstrate the combined power of the Company's proprietary dataset and the full power of the analytical tools present within the Lumin Analytic Engine, Champions has built in-house computational target discovery expertise to identify and prioritize novel therapeutic targets. This approach relies heavily on AI and machine learning algorithms. Computational approaches have emerged as a central mechanism for target discovery in recent years, but often suffer from the use of incomplete or misleading datasets. Champions' computational approach leverages a more complete data set that is derived from tumor models with a more authentic tumor cell biology and heterogeneity. As a result, the computational teams at Champions can identify targets that are often overlooked or missed when using other datasets. The extensive pre-clinical platform available at Champions' research facilities also allows for a quick and efficient experimental validation.
The areas of focus for Champions' therapeutic target discovery include, amongst others, immune modulation, cell surface proteins for drug conjugates, and intracellular ligases and kinases that are required for tumor cell survival. Some of the targets that have been validated exploit the intact and complex metabolic, inflammatory and ubiquitin pathways, as well as a more representative global protein expression level, present within Champions' tumor models. Programs that have been established around these targets leverage various therapeutic modalities, including both small and large molecule approaches. The commercial strategy for each program will vary, and can include independent development, co-development, or out-licensing.
Ronnie Morris, MD, President and CEO, said "It's amazing to have reached the point where we see the full realization of our business model. As you know, the foundational core of the Champions business is the proprietary dataset which we have amassed over the last decade. On top of this core, we developed a set of market-leading technology-enabled platform services which fueled our becoming a fast growing & profitable company. Last year we released our software solution, Lumin Bioinformatics, which allows our customers a new way to access & search insights in our datasets. And now, we are excited to unveil discovery and innovation. The synergy of these three vibrant business units allows us to leverage our core in higher value and higher margin businesses that would accelerate our revenue and long-term profit growth."
"Drug discovery and development is the natural next step for Champions," said Michael Ritchie, PhD, MBA, Chief Commercial Officer at Champions Oncology. "We have established such a strong leadership position in delivering the highest quality of science over the years. When we coupled that with our unparalleled dataset and our newly built computational capabilities, we saw the potential to be transformative in drug development. I am amazed every day at what our drug discovery teams are delivering and look forward to seeing these programs mature towards the clinic."
About Champions Oncology
Champions Oncology is a technology-driven research organization that develops innovative therapeutics against cancer targets, offers groundbreaking research software as a service, and provides end-to-end R&D services to biopharma organizations. Champions Oncology is actively engaged in the transformation of drug discovery and development of oncology therapeutics. For more information, please visit www.ChampionsOncology.com.
Media Contact:
Rachel Bunting, MS, MBA
Sr. Director, Head of Marketing
Marketing@ChampionsOncology.com
Website: www.championsoncology.com
Facebook: https://www.facebook.com/championsoncology/
LinkedIn: https://www.linkedin.com/company/champions-oncology-inc-/
Twitter: https://twitter.com/ChampionsOncol1
Instagram: https://www.instagram.com/championsoncology/
SOURCE: Champions Oncology, Inc.
View source version on accesswire.com:
https://www.accesswire.com/656959/Champions-Oncology-Announces-an-Expanded-Corporate-Strategy-to-Include-Drug-Discovery-and-Development
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Chervon Names Devin Murray Director of Sales - Northern Division19.10.2026 15:00:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / October 19, 2026 / Devin Murray joins Chervon as Director of Sales - Northern Division, effective October 19, 2026, reporting to Thomas Kentouris, Vice President of Field Sales. Murray joins Chervon after completing a six-year fast track career in TTI sales and sales management. Most recently, he was a Key End User Account Manager for Milwaukee charged with growing the pro tool business with large end users. Murray's exceptional recruiting skills and leadership skills enabled him to build, manage and inspire highly effective sales teams at the store level. His account management prowess resulted in outstanding sales results and strong partnerships with multiple national accounts. "Early in his impressive career, Devin was identified as a high potential future superstar executive," said Thomas Kentouris. "His large end user pro tool experience is exactly what we need to help build our pro tool leadership position. His inspiring leadership skills combin
Chervon Names Krystle Adams Director of Sales Recruiting19.10.2026 15:00:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / October 19, 2026 / Krystle Adams joins Chervon as Director of Sales Recruiting, effective October 19, 2026, reporting to Matt DeFeo, SVP of Sales, Training and Recruiting. Over the past 9+ years, Adams has advanced through a series of increasingly responsible sales and recruiting positions at TTI. Earlier in her impressive career, Krystle distinguished herself as an outstanding sales representative and sales manager delivering consistently strong results. Most recently, she was a National Recruiting Operations Manager responsible for leading, coordinating, and implementing recruiting efforts across campuses nationwide. Krystle has demonstrated exceptional skills in developing and leading campus and field sales recruiting efforts. She also designed and executed a thriving national college internship program. "I feel incredibly fortunate to now have Krystle Adams in place to launch Chervon campus recruiting," said Matt DeFeo, SVP of Sales, Training and
Chervon Names Terry Lucero Director of National Accounts - Industrial19.10.2026 15:00:00 CEST | Press release
NAPERVILLE, IL / ACCESS Newswire / October 19, 2026 / Terry Lucero joins Chervon as Director of National Accounts - Industrial, effective October 19, 2026, reporting to Jeff Campbell, Senior Vice President of Industrial Commercial Sales. Lucero brings 25+ years of extensive experience in building professional tool businesses at national accounts, regional accounts, at the store level and at the end user level. Lucero started his career at Dewalt where he advanced through a series of sales, sales management and end user marketing positions over 5 years driving professional tool growth. Lucero went on to WW Grainger where he progressed through a series of business development and sales management positions. He was also a sales manager of professional equipment at United Rentals. Most recently, Lucero served as a director of sales at APEX Tool Group for the Americas. "Terry's impressive pro tool experience in industrial distribution, national account management and end user marketing make
Tenstorrent Announces a $1.5B Series E at a $6.2B Valuation19.10.2026 14:00:00 CEST | Press release
SANTA CLARA, CA / ACCESS Newswire / October 19, 2026 / Tenstorrent, the AI computing company, has closed $1.5B in Series E funding at a $6.2B post-money valuation. The round was led by Trace Capital and Innovation X, with participation from new and existing investors including Agostinelli Group, ARK Invest, Brett Barna, Cadence Ventures, Eclipse, Fidelity Management & Research Company, Maverick Silicon, Morgan Stanley, Protagonist, Sandisk, T. Rowe Price*, Tether Investments, Troluce Capital, Virtu Financial, and XTX Markets. Tenstorrent will use the capital to deploy Galaxy servers at scale, continuing to serve open-weight models across LLMs and video generation, and advance the AI and CPU IP it licenses to customers designing their own silicon. Tenstorrent sells AI compute at every level of the stack - from a single card or workstation to racks, superclusters, and custom IP. With an open-source software stack, developers can run frontier models locally and enterprises can deploy mode
OxyDew Analyzer: One Compact Instrument, Two Critical Gas Measurements19.10.2026 08:00:00 CEST | Press release
NAVAN, IE / ACCESS Newswire / October 19, 2026 / DwyerOmega introduces the new Ntron OxyDew Analyzer, a fully integrated solution that combines oxygen and moisture dew-point measurement in a single, compact wall-mountable analyzer. The result: fewer instruments to install, wire, and maintain, without sacrificing the accuracy and reliability that critical gas quality monitoring demands. By uniting two proven sensing technologies in one instrument, OxyDew cuts equipment costs, simplifies installation, and reduces ongoing maintenance, all without compromising performance. Operators monitor oxygen concentration and dew point simultaneously through a 3-inch color touchscreen, giving them a single point of control instead of two separate systems. OxyDew is available now throughout Europe and Asia Pacific. Integrated Dual Measurement for Reliable Process Monitoring At the heart of OxyDew is the integration of the proven Ntron SenzTx Oxygen Transmitter and Michell Easidew Dew-Point Transmitter
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom